ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber Sells 17,238 Shares

ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber sold 17,238 shares of ProKidney stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $2.50, for a total value of $43,095.00. Following the sale, the senior vice president now directly owns 172,432 shares of the company’s stock, valued at approximately $431,080. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

ProKidney Stock Up 4.4 %

PROK stock opened at $2.84 on Thursday. ProKidney Corp. has a 52-week low of $1.12 and a 52-week high of $13.51. The company’s 50-day simple moving average is $1.56 and its 200-day simple moving average is $1.80. The firm has a market cap of $651.33 million, a P/E ratio of -4.98 and a beta of 1.08.

ProKidney (NASDAQ:PROK) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.10. On average, analysts anticipate that ProKidney Corp. will post -0.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ProKidney

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its position in shares of ProKidney by 978.2% in the second quarter. BlackRock Inc. now owns 3,316,973 shares of the company’s stock valued at $37,117,000 after purchasing an additional 3,009,342 shares during the period. State Street Corp increased its stake in ProKidney by 1,540.0% during the 2nd quarter. State Street Corp now owns 990,259 shares of the company’s stock worth $11,081,000 after buying an additional 929,878 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of ProKidney by 450.9% during the second quarter. Geode Capital Management LLC now owns 760,823 shares of the company’s stock valued at $8,514,000 after acquiring an additional 622,728 shares during the last quarter. Morgan Stanley lifted its position in shares of ProKidney by 5.8% in the fourth quarter. Morgan Stanley now owns 10,947,495 shares of the company’s stock valued at $75,100,000 after acquiring an additional 595,839 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of ProKidney by 1,451.6% during the second quarter. Northern Trust Corp now owns 452,186 shares of the company’s stock worth $5,060,000 after purchasing an additional 423,043 shares in the last quarter. Hedge funds and other institutional investors own 51.59% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on PROK shares. Bank of America lowered shares of ProKidney from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 2nd. Morgan Stanley assumed coverage on ProKidney in a report on Thursday, March 7th. They issued an “equal weight” rating and a $3.00 price target for the company.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.